(MRK) Merck KGaA - Ratings and Ratios
LifeScienceTools, HealthcareDrugs, ElectronicMaterials
MRK EPS (Earnings per Share)
MRK Revenue
Description: MRK Merck KGaA
Merck KGaA is a diversified science and technology company operating in three main segments: Life Science, Healthcare, and Electronics. The Life Science segment provides a range of products and services for research, development, and manufacturing in the pharmaceutical, biotech, and industrial sectors, including process development expertise, testing kits, and reagents. The Healthcare segment focuses on developing and marketing prescription drugs and biopharmaceuticals for various therapeutic areas, such as oncology, neurology, and immunology. The Electronics segment supplies materials and solutions for the semiconductor and display industries.
From a financial perspective, Merck KGaA has a market capitalization of approximately €47.5 billion, indicating a significant presence in the global pharmaceutical and technology industries. The companys price-to-earnings (P/E) ratio is around 17.43, suggesting a relatively reasonable valuation compared to its earnings. The forward P/E ratio is lower, at 12.56, indicating potential for future earnings growth. The return on equity (RoE) is around 9.67%, which is a respectable figure, although it may not be outstanding compared to some peers.
Some key performance indicators (KPIs) to consider when evaluating Merck KGaA include its revenue growth, operating margin, and research and development (R&D) expenditure as a percentage of sales. The companys R&D focus is evident from its multiple collaborations and licensing agreements, such as those with Debiopharm International SA, Jiangsu Hengrui Pharmaceuticals Co. Ltd., and Abbisko Therapeutics Co. Ltd. These partnerships aim to develop and commercialize new treatments for various diseases, including cancer and multiple sclerosis. A review of Merck KGaAs dividend yield and payout ratio could also provide insights into its ability to generate cash and return value to shareholders.
To further analyze Merck KGaAs prospects, it would be essential to examine its product pipeline, particularly in the Healthcare segment, where the company is developing new treatments for various therapeutic areas. The competitive landscape, including the positioning of its products and services relative to peers, is also crucial. Additionally, an assessment of the companys Electronics segment, including its supply chain and customer base, could provide insights into its growth potential and potential risks.
MRK Stock Overview
| Market Cap in USD | 54,841m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
MRK Stock Ratings
| Growth Rating | -65.1% |
| Fundamental | 56.0% |
| Dividend Rating | 40.0% |
| Return 12m vs S&P 500 | -44.5% |
| Analyst Rating | - |
MRK Dividends
| Dividend Yield 12m | 1.86% |
| Yield on Cost 5y | 1.90% |
| Annual Growth 5y | -3.29% |
| Payout Consistency | 90.0% |
| Payout Ratio | 27.2% |
MRK Growth Ratios
| Growth Correlation 3m | -54% |
| Growth Correlation 12m | -95.8% |
| Growth Correlation 5y | -28.2% |
| CAGR 5y | -11.98% |
| CAGR/Max DD 3y | -0.26 |
| CAGR/Mean DD 3y | -0.57 |
| Sharpe Ratio 12m | -1.56 |
| Alpha | 0.07 |
| Beta | 0.710 |
| Volatility | 24.09% |
| Current Volume | 211k |
| Average Volume 20d | 198.6k |
| Stop Loss | 104.4 (-3%) |
| Signal | 0.56 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (2.86b TTM) > 0 and > 6% of Revenue (6% = 1.27b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.01% (prev 14.93%; Δ -3.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 3.81b > Net Income 2.86b (YES >=105%, WARN >=100%) |
| Net Debt (-1.17b) to EBITDA (5.87b) ratio: -0.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.24 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (434.8m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 58.51% (prev 58.22%; Δ 0.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.65% (prev 41.84%; Δ 1.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.24 (EBITDA TTM 5.87b / Interest Expense TTM 322.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.83
| (A) 0.05 = (Total Current Assets 12.20b - Total Current Liabilities 9.86b) / Total Assets 47.35b |
| (B) 0.49 = Retained Earnings (Balance) 23.34b / Total Assets 47.35b |
| (C) 0.08 = EBIT TTM 3.94b / Avg Total Assets 48.61b |
| (D) 1.28 = Book Value of Equity 24.44b / Total Liabilities 19.02b |
| Total Rating: 3.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 55.95
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 3.12% = 1.56 |
| 3. FCF Margin 8.39% = 2.10 |
| 4. Debt/Equity 0.43 = 2.41 |
| 5. Debt/Ebitda 2.09 = -0.18 |
| 6. ROIC - WACC (= 2.94)% = 3.67 |
| 7. RoE 9.85% = 0.82 |
| 8. Rev. Trend -52.36% = -3.93 |
| 9. EPS Trend -50.05% = -2.50 |
What is the price of MRK shares?
Over the past week, the price has changed by -0.87%, over one month by -2.80%, over three months by -3.97% and over the past year by -34.21%.
Is Merck KGaA a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRK is around 90.77 EUR . This means that MRK is currently overvalued and has a potential downside of -15.68%.
Is MRK a buy, sell or hold?
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 147.5 | 37% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 99.8 | -7.3% |
MRK Fundamental Data Overview
Market Cap EUR = 46.41b (46.41b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 1.57b EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 16.1988
P/E Forward = 11.2486
P/S = 2.1873
P/B = 1.6602
P/EG = 1.2495
Beta = 0.61
Revenue TTM = 21.22b EUR
EBIT TTM = 3.94b EUR
EBITDA TTM = 5.87b EUR
Long Term Debt = 9.16b EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.10b EUR (from shortTermDebt, last quarter)
Debt = 12.27b EUR (Calculated: Short Term 3.10b + Long Term 9.16b)
Net Debt = -1.17b EUR (from netDebt column, last quarter)
Enterprise Value = 57.11b EUR (46.41b + Debt 12.27b - CCE 1.57b)
Interest Coverage Ratio = 12.24 (Ebit TTM 3.94b / Interest Expense TTM 322.0m)
FCF Yield = 3.12% (FCF TTM 1.78b / Enterprise Value 57.11b)
FCF Margin = 8.39% (FCF TTM 1.78b / Revenue TTM 21.22b)
Net Margin = 13.49% (Net Income TTM 2.86b / Revenue TTM 21.22b)
Gross Margin = 58.51% ((Revenue TTM 21.22b - Cost of Revenue TTM 8.80b) / Revenue TTM)
Tobins Q-Ratio = 2.34 (Enterprise Value 57.11b / Book Value Of Equity 24.44b)
Interest Expense / Debt = 0.64% (Interest Expense 79.0m / Debt 12.27b)
Taxrate = 21.24% (751.0m / 3.54b)
NOPAT = 3.10b (EBIT 3.94b * (1 - 21.24%))
Current Ratio = 1.24 (Total Current Assets 12.20b / Total Current Liabilities 9.86b)
Debt / Equity = 0.43 (Debt 12.27b / last Quarter total Stockholder Equity 28.26b)
Debt / EBITDA = 2.09 (Net Debt -1.17b / EBITDA 5.87b)
Debt / FCF = 6.89 (Debt 12.27b / FCF TTM 1.78b)
Total Stockholder Equity = 29.08b (last 4 quarters mean)
RoA = 6.05% (Net Income 2.86b, Total Assets 47.35b )
RoE = 9.85% (Net Income TTM 2.86b / Total Stockholder Equity 29.08b)
RoCE = 10.31% (Ebit 3.94b / (Equity 29.08b + L.T.Debt 9.16b))
RoIC = 9.87% (NOPAT 3.10b / Invested Capital 31.46b)
WACC = 6.93% (E(46.41b)/V(58.68b) * Re(8.63%)) + (D(12.27b)/V(58.68b) * Rd(0.64%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 0.0 | Cagr: -0.01%
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.56% ; FCFE base≈1.83b ; Y1≈1.66b ; Y5≈1.45b
Fair Price DCF = 182.5 (DCF Value 23.58b / Shares Outstanding 129.2m; 5y FCF grow -11.52% → 3.0% )
EPS Correlation: -50.05 | EPS CAGR: -1.74% | SUE: -0.80 | # QB: 0
Revenue Correlation: -52.36 | Revenue CAGR: -3.56% | SUE: N/A | # QB: None